YZYaowei Zhang

Yaowei Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yaowei Zhang has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Yi Ding

    Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China

    8 shared publications
  • Keli Chen

    Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, Guangzhou, China

    4 shared publications
  • Lu Yu

    Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China

    4 shared publications
  • Yuqin Zhang

    Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China

    4 shared publications
  • Huilian Zhang

    Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China

    3 shared publications
  • Yajing Wen

    Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China

    3 shared publications

Latest Publications

  • Open Access

    Prognostic stratification in metastatic early-onset colorectal cancer: development and independent external validation of a survival model

    by Yajing Wen, Huilian Zhang, Mengya Du, Jiaxin Duan, Sihan Li, Yingchun Zhou, Tingyu Mou, Yuqin Zhang, Yi Ding, Yaowei Zhang

  • Oral and gut microbiota profiles in patients with locally advanced rectal cancer with varying responses to neoadjuvant chemoradiotherapy

    by Yajing Wen, Ziqian Luo, Zhemin Li, Kexin Li, Jiaying Li, Shengqi Yin, Yishu Zou, Huilian Zhang, Yuqin Zhang, Keli Chen, et al.

  • Open Access

    Training and validation of a nomogram for predicting synchronous distant organ metastasis in patients with very-early-onset colorectal cancer

    by Yajing Wen, Zhemin Li, Huilian Zhang, Jinyu Huang, Yuqin Zhang, Yi Ding, Jianbiao Xiao, Yaowei Zhang

    Original Article Training and validation of a nomogram for predicting synchronous distant organ metastasis in patients with very-early-onset colorectal cancer Yajing Wen, Zhemin Li, Huilian Zhang, Jinyu Huang, Yuqin Zhang, Yi Ding, Jianbiao Xiao, Yaowei Zhang

  • Open Access

    CS@LGG as a therapeutic biomaterial for acute radiation-induced bowel injury alleviation

    by Xinyi Gu, Lu Yu, Xusheng Wang, Shengqi Yin, Yilin Zheng, Zhihao Zheng, Yaowei Zhang, Keli Chen, Yuqing Zhang, Yi Ding

    Acute radiation-induced bowel injury is a serious and inevitable adverse effect of pelvic radiotherapy, with few standardized therapies available in clinical practice. Interestingly, fecal microbiota transplantation (FMT) has been shown to be an effective therapeutic method. Among the probiotics, Lactobacillus rhamnosus GG (LGG) has the most prominent effect. However, due to its poor tolerance and viability in vitro and its potential to cause bacteremia in vivo, this study chose a natural and biosafe polymer called chitosan (CS) to act as a carrier, avoiding the aforementioned limitations of FMT. In this study, we successfully synthesized a curative probiotic biomaterial, named CS@LGG, to protect the intestinal epithelium from radiation-induced damage. It repaired the intestinal barrier with increased expression of occludin, claudin-3, and Ki-67, while decreasing γH2A.X. In addition, it enabled clearance of local and systemic pro-inflammatory factors, such as interleukin (IL)-6, IL1-β, and tumor necrosis factor alpha. Surprisingly, this biomaterial demonstrated good biosafety in vitro and in vivo, with a certain extent of tumor suppression. Furthermore, this study shed light on the possible mechanism underlying its therapeutic effect. RNA sequencing analysis indicated that overproduction of immunoglobulin A on local mucosa might be the core factor of damaged intestinal microenvironment leading to acute radiation-induced bowel injury. In conclusion, CS@LGG created in this work is a biosafe and effective new probiotic biomaterial that holds promise in the treatment and relief of acute radiation-induced bowel injury.


  • Open Access

    Impact of gut microbiome on radiotherapy and immunotherapy efficacy in microsatellite-stable colorectal cancer: role of propionic acid and B. fragilis

    by Lu Yu, Qiqing Guo, Xinyi Gu, Zihuan Wang, Jiaying Li, Xusheng Wang, Zi Xu, Yafang Wang, Yuqin Zhang, Yaowei Zhang, et al.

    Background: Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths worldwide. While immunotherapy is effective in microsatellite instability-high (MSI-H) CRC, its benefits in microsatellite-stable (MSS) CRC are limited. Radiotherapy may modify the immune microenvironment in MSS-CRC, enhancing immunotherapy efficacy, but individual responses vary. Methods: We employed MSS-CRC mouse models to examine the effects of combined radiotherapy and immunotherapy, with and without antibiotics (ABX). Various analyses, including metagenomic, nontargeted metabolomic, and gas chromatography-mass spectrometry (GC-MS), were performed to identify factors influencing treatment outcomes. Flow cytometry, immunohistochemistry and in vivo antibody blockade experiments assessed the role of metabolites and bacteria on CD8+ T cell infiltration and treatment responses, complemented by transcriptomic sequencing and molecular biology experiments. Results: Our analyses identified propionic acid and Bacteroides fragilis (B. fragilis) as crucial factors enhancing the efficacy of combined therapies in MSS-CRC. Both propionic acid and B. fragilis improved CD8+ T cell infiltration and treatment outcomes, with molecular assays indicating that propionic acid facilitates H3K14 acetylation, activating the Meox1-Cxcr6/Ccl5 axis. Conclusions: This study highlights the pivotal role of the gut microbiome, specifically propionic acid and B. fragilis, in modulating the efficacy of combined radiotherapy and immunotherapy in MSS-CRC.


  • KIAA1549 promotes the development and chemoresistance of colorectal cancer by upregulating ERCC2

    by Feng Ye, Yuwen Xie, Mingdao Lin, Yang Liu, Yuan Fang, Keli Chen, Yaowei Zhang, Yi Ding

    Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. Chemotherapy is the mainstay of treatment for patients with CRC in II-IV stages. Resistance to chemotherapy occurs commonly, which results in treatment failure. Therefore, the identification of novel functional biomarkers is essential for recognizing high-risk patients, predicting recurrence, and developing new therapeutic strategies. Herein, we assessed the roles of KIAA1549 in promoting tumor development and chemoresistance in colorectal cancer. As a result, we found that KIAA1549 expression is up-regulation in CRC. Public databases revealed a progressive up-regulation of KIAA1549 expression from adenomas to carcinomas. Functional characterization uncovered that KIAA1549 promotes tumor malignant phenotypes and boosts the chemoresistance of CRC cells in an ERCC2-dependent manner. Inhibition of KIAA1549 and ERCC2 effectively enhanced the sensitivity to chemotherapeutic drugs oxaliplatin and 5-fluorouracil. Our findings suggest that endogenous KIAA1549 might function as a tumor development-promoting role and trigger chemoresistance in colorectal cancer partly by upregulating DNA repair protein ERCC2. Hence, KIAA1549 could be an effective therapeutic target for CRC and inhibition of KIAA1549 combined with chemotherapy might be a potential therapeutic strategy in the future.


  • Open Access

    TXN inhibitor impedes radioresistance of colorectal cancer cells with decreased ALDH1L2 expression via TXN/NF-κB signaling pathway

    by Lu Yu, Qiqing Guo, Ziqian Luo, Yongjia Wang, Jiawen Weng, Yuchuan Chen, Weijie Liang, Yiyi Li, Yuqin Zhang, Keli Chen, et al.

    Background: Colorectal cancer (CRC) is prevalent worldwide and is often challenged by treatment failure and recurrence due to resistance to radiotherapy. Here, we aimed to identify the elusive underlying molecular mechanisms of radioresistance in CRC. Methods: Weighted gene co-expression network analysis was used to identify potential radiation-related genes. Colony formation and comet assays and multi-target single-hit survival and xenograft animal models were used to validate the results obtained from the bioinformatic analysis. Immunohistochemistry was performed to examine the clinical characteristics of ALDH1L2. Co-immunoprecipitation, immunofluorescence and flow cytometry were used to understand the molecular mechanisms underlying radioresistance. Results: Bioinformatic analysis, in vitro, and in vivo experiments revealed that ALDH1L2 is a radiation-related gene, and a decrease in its expression induces radioresistance in CRC cells by inhibiting ROS-mediated apoptosis. Patients with low ALDH1L2 expression exhibit resistance to radiotherapy. Mechanistically, ALDH1L2 interacts with thioredoxin (TXN) and regulates the downstream NF-κB signaling pathway. PX-12, the TXN inhibitor, overcomes radioresistance due to decreased ALDH1L2. Conclusions: Our results provide valuable insights into the potential role of ALDH1L2 in CRC radiotherapy. We propose that the simultaneous application of TXN inhibitors and radiotherapy would significantly ameliorate the clinical outcomes of patients with CRC having low ALDH1L2.


  • Textual analysis on the perceived value of cultural tourists in Beijing’s old palace(Forbidden City)

    by Shiqian Hu, Yaowei Zhang, Seung-An Jung

    ?? ?????????? ??¡?? ??ȣ?ۿ? ?̷??? ??????? ????¡ ?????? ???? ??? ?????? ??Ʈ??ũ ???? ?????͸? ????? TF-IDF ?˰??????? ???? ???????? ?ν??ϴ? Ű???带 ?????ϰ? ?????? ?ν? ??Ҹ? ????Ͽ???. ?̸? ??????? LDA ?˰??????? ????Ͽ? ???????? ?ν? ?????? ?ֿ? ????ġ?? ?м??ϰ?, ???????? ?ν? ????? ???? ?????? ?????Ͽ? ?׵??? ?νİ?ġ ???? ??Ŀ???? ???? ?????ϰ??? ?Ѵ?. ?????? ?????? ù°, ?????? ?ν? ??ҷδ? ?ַ? ?????????? ???帶ũ, ???? ???? ???, ?????? ???? ???, ????? ?ν? ??? ?? ??????? ??? ?? 5???? ???ַ? ???Ǿ???. ??°, ???????? ?ν??ϴ? ?ó??????? ??ġ, ???? ǰ???? ??ġ, ?????? ?????? ??ġ, ?ν??? ??ġ ?? ????????? ??ġ?? ?ַ? ?????Ǵ? ?????? ?ν? ??Ҵ? ????? ???????? ?ִ?. ??°, ?????? ?ν? ??ҿ? ?νİ?ġ ?????? ?????? ???? ?νİ?ġ ???? ??Ŀ?????? ???? ?????ϴ? ?߿??? ????̴?. ??ȭ?? ?????? ???? ???Ű? ??ȭ?? ????????? ??ǰ?? ?????? ?????ϴ? ???????? ???δ? ?ù? ?????ν? ??ġ ????, ?ù? ????????, ???????? ?????? ??ȭ, ????Ʈ ???? ?Ǽ??? ?߽??ؾ? ?Ѵ?.

  • Open Access

    Development of a Joint Prediction Model Based on Both the Radiomics and Clinical Factors for Predicting the Tumor Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer

    by Yang Liu, Feng-Jiao Zhang, Xi-Xi Zhao, Yuan Yang, Chun-Yi Liang, Li-Li Feng, Xiang-Bo Wan, Yi Ding, Yao-Wei Zhang

    Purpose: Neoadjuvant chemoradiotherapy (nCRT) has become the standard treatment for locally advanced rectal cancer (LARC). However, the accuracy of traditional clinical indicators in predicting tumor response is poor. Recently, radiomics based on magnetic resonance imaging (MRI) has been regarded as a promising noninvasive assessment method. The present study was conducted to develop a model to predict the pathological response by analyzing the quantitative features of MRI and clinical risk factors, which might predict the therapeutic effects in patients with LARC as accurately as possible before treatment. Patients and Methods: A total of 82 patients with LARC were enrolled as the training cohort and internal validation cohort. The pre-CRT MRI after pretreatment was acquired to extract texture features, which was finally selected through the minimum redundancy maximum relevance (mRMR) algorithm. A support vector machine (SVM) was used as a classifier to classify different tumor responses. A joint radiomics model combined with clinical risk factors was then developed and evaluated by receiver operating characteristic (ROC) curves. External validation was performed with 107 patients from another center to evaluate the applicability of the model. Results: Twenty top image texture features were extracted from 6192 extracted-radiomic features. The radiomics model based on high-spatial-resolution T2-weighted imaging (HR-T2WI) and contrast-enhanced T1-weighted imaging (T1+C) demonstrated an area under the curve (AUC) of 0.8910 (0.8114– 0.9706) and 0.8938 (0.8084– 0.9792), respectively. The AUC value rose to 0.9371 (0.8751– 0.9997) and 0.9113 (0.8449– 0.9776), respectively, when the circumferential resection margin (CRM) and carbohydrate antigen 19-9 (CA19-9) levels were incorporated. Clinical usefulness was confirmed in an external validation cohort as well (AUC, 0.6413 and 0.6818). Conclusion: Our study indicated that the joint radiomics prediction model combined with clinical risk factors showed good predictive ability regarding the treatment response of tumors as accurately as possible before treatment.


  • Open Access

    Role of an MDM4 polymorphism in the early age of onset of nasopharyngeal carcinoma

    by Yao Wei Zhang, Jian Guan, Yong Zhang, Yu Rong Qiu, Long Hua Chen

    Mouse double minute 4 (MDM4) is a critical negative regulator of the tumor suppressor p53. The results of studies have revealed that an MDM4 polymorphism (rs1563828) may contribute to the earlier onset of several malignant diseases. However, the correlation between this polymorphism and nasopharyngeal carcinoma (NPC) susceptibility has not been explored. We performed a case-control study with 210 NPC patients and 200 healthy controls. Significant associations were found when comparing the age of onset of NPC according to the rs1563828 genotype (P=0.01). The average age of onset of NPC in patients with the TT, CC and CT genotypes was 39.3, 48.2 and 45.5 years, respectively. Homozygous variant (TT) carriers developed NPC at an earlier age than homozygous (CC) carriers, such that the age of onset was accelerated by 8.9 years (P=0.002). Our data suggest that rs1563828 is a modifier of the age of onset of NPC in the population studied. The age of onset for NPC with TT homozygotes was earlier than CC carriers.